- Home
- SNDX vs KFRC Comparison
SNDX vs KFRC Comparison
Compare SNDX & KFRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- KFRC
- Stock Information
- Founded
- SNDX 2005
- KFRC 1962
- Country
- SNDX United States
- KFRC United States
- Employees
- SNDX N/A
- KFRC N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- KFRC Professional Services
- Sector
- SNDX Health Care
- KFRC Consumer Discretionary
- Exchange
- SNDX Nasdaq
- KFRC Nasdaq
- Market Cap
- SNDX 1.2B
- KFRC N/A
- IPO Year
- SNDX 2016
- KFRC 1995
- Fundamental
- Price
- SNDX $14.54
- KFRC $54.16
- Analyst Decision
- SNDX Strong Buy
- KFRC Buy
- Analyst Count
- SNDX 10
- KFRC 3
- Target Price
- SNDX $36.20
- KFRC $66.67
- AVG Volume (30 Days)
- SNDX 2.1M
- KFRC 95.7K
- Earning Date
- SNDX 02-25-2025
- KFRC 02-03-2025
- Dividend Yield
- SNDX N/A
- KFRC 2.78%
- EPS Growth
- SNDX N/A
- KFRC N/A
- EPS
- SNDX N/A
- KFRC 2.68
- Revenue
- SNDX $16,000,000.00
- KFRC $1,405,308,000.00
- Revenue This Year
- SNDX N/A
- KFRC N/A
- Revenue Next Year
- SNDX N/A
- KFRC $0.84
- P/E Ratio
- SNDX N/A
- KFRC $20.41
- Revenue Growth
- SNDX N/A
- KFRC N/A
- 52 Week Low
- SNDX $12.06
- KFRC $52.96
- 52 Week High
- SNDX $25.34
- KFRC $74.79
- Technical
- Relative Strength Index (RSI)
- SNDX 57.25
- KFRC 38.31
- Support Level
- SNDX $13.61
- KFRC $53.15
- Resistance Level
- SNDX $14.62
- KFRC $55.40
- Average True Range (ATR)
- SNDX 0.62
- KFRC 1.18
- MACD
- SNDX 0.15
- KFRC -0.12
- Stochastic Oscillator
- SNDX 91.20
- KFRC 23.10
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.